ArticleFrontiers in endocrinology2026
Chestnut-derived ellagitannins (FT50) protect against western diet-induced metabolic dysfunction and preserve beta cell function in mice.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Western diet (WD) consumption accelerates the development of metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM). This study investigated whether chestnut-derived ellagitannins (FT50) modulate early metabolic alterations associated with WD feeding in C57BL/6J male mice. Methods: Male C57BL/6J mice were fed either a western diet (WD) or a WD supplemented with chestnut extract (FT50) for 12 weeks. Body weight, adiposity, glucose tolerance, and indices of insulin action were monitored throughout the study. Glucose and insulin homeostasis were assessed by measuring fasting glucose levels, insulin levels, and the HOMA-IR index. Pancreatic function was evaluated by Results: WD feeding induced significant body weight gain, adiposity, hyperglycemia, glucose intolerance, changes consistent with impaired insulin action, and partially compensatory hyperinsulinemia. Supplementation with FT50 prevented weight gain and fat accumulation, reduced organ hypertrophy, and was associated with improved glucose and insulin-related parameters without affecting the caloric intake. FT50-fed mice showed improved glucose tolerance from week 4 onward, accompanied by a lower HOMA-IR values and reduced hyperinsulinemia, consistent with improved indirect markers of insulin action relative to WD-fed mice. Conclusions: In sum, these effects indicate reduced beta cell excitability and are consistent with an attenuation of early metabolic alterations under WD conditions. Overall, these findings suggest that FT50 supplementation modulates early WD-induced metabolic changes in male mice. However, the study is limited to early-stage alterations, does not address later stages of metabolic disease, and does not establish direct effects on insulin sensitivity. Within these constraints, chestnut extract represents a potentially promising bioactive dietary intervention for modulating early metabolic responses to WD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.